<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39469670</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2001-0370</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Computational and structural biotechnology journal</Title><ISOAbbreviation>Comput Struct Biotechnol J</ISOAbbreviation></Journal><ArticleTitle>ACVPICPred: Inhibitory activity prediction of anti-coronavirus peptides based on artificial neural network.</ArticleTitle><Pagination><StartPage>3625</StartPage><EndPage>3633</EndPage><MedlinePgn>3625-3633</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.csbj.2024.09.015</ELocationID><Abstract><AbstractText>Peptides, as small molecular compounds, exhibit prominent advantages in the inhibition of coronaviruses due to their safety, efficacy, and specificity, holding great promise as drugs against coronaviruses. The rapid and efficient determination of the activity of anti-coronavirus peptides (ACovPs) can greatly accelerate the development of drugs for treating coronavirus-related diseases. Hence, we present ACVPICPred, a computational model designed to predict the inhibitory activity of ACovPs based on their sequences and structural information. By leveraging bioinformatics tools AlphaFold3 for structural predictions and several feature extraction methods, the model integrates both sequence and structural features to enhance prediction accuracy. To address the limitations of existing datasets, we employed data augmentation techniques, including the introduction of noise and the SMOGN, to improve the model robustness. The model's performance was evaluated through five-fold cross-validation, achieving a Pearson correlation coefficient of 0.7668 (<i>p</i> &lt; 0.05) and an <i>R</i>² of 0.5880 on the training dataset. Overall, in our study, compared to models that only use sequence features, models that combine structural features have achieved more robust results in various evaluation metrics. ACVPICPred is freely accessible at the following URL: http://i.uestc.edu.cn/acvpICPred/main/Main.php.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yifei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Bowen</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chunying</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jian</LastName><ForeName>Guifen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Life Science and Technology, University of Electronic Science and Technology of China, No.2006, Xiyuan Ave, West Hi‑Tech Zone, Chengdu 6173001, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Bifang</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Medical College, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>State Key Laboratory of Public Big Data, Guizhou University, Huaxi District, Guiyang 550025, Guizhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Comput Struct Biotechnol J</MedlineTA><NlmUniqueID>101585369</NlmUniqueID><ISSNLinking>2001-0370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-coronavirus peptides</Keyword><Keyword MajorTopicYN="N">Artificial neural network</Keyword><Keyword MajorTopicYN="N">Inhibitory concentration</Keyword><Keyword MajorTopicYN="N">Regression</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted without any commercial or financial relationships that could be perceived as potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>29</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39469670</ArticleId><ArticleId IdType="pmc">PMC11513478</ArticleId><ArticleId IdType="doi">10.1016/j.csbj.2024.09.015</ArticleId><ArticleId IdType="pii">S2001-0370(24)00303-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Shahrajabian M.H., Sun W., Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother. 2021;17(1):62–83. doi: 10.1080/21645515.2020.1797369.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2020.1797369</ArticleId><ArticleId IdType="pmc">PMC7872062</ArticleId><ArticleId IdType="pubmed">32783700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Grunewald M., Perlman S. Coronaviruses: an updated overview of their replication and pathogenesis. Methods Mol Biol. 2020;2203:1–29. doi: 10.1007/978-1-0716-0900-2_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0900-2_1</ArticleId><ArticleId IdType="pmc">PMC7682345</ArticleId><ArticleId IdType="pubmed">32833200</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasoksuz M., Kilic S., Sarac F. Coronaviruses and SARS-COV-2. Turk J Med Sci. 2020;50(SI-1):549–556. doi: 10.3906/sag-2004-127.</Citation><ArticleIdList><ArticleId IdType="doi">10.3906/sag-2004-127</ArticleId><ArticleId IdType="pmc">PMC7195990</ArticleId><ArticleId IdType="pubmed">32293832</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization W.H. (2024) COVID-19 epidemiological update – 13 August 2024. https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-170.</Citation></Reference><Reference><Citation>Zumla A., Chan J.F., Azhar E.I., Hui D.S., Yuen K.Y. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347. doi: 10.1038/nrd.2015.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrd.2015.37</ArticleId><ArticleId IdType="pmc">PMC7097181</ArticleId><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan Y., Jiao B., Qu L., Yang D., Liu R. The development of COVID-19 treatment. Front Immunol. 2023;14 doi: 10.3389/fimmu.2023.1125246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1125246</ArticleId><ArticleId IdType="pmc">PMC9909293</ArticleId><ArticleId IdType="pubmed">36776881</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei X., Dong X., Ma R., Wang W., Xiao X., et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11(1):3810. doi: 10.1038/s41467-020-17665-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17665-9</ArticleId><ArticleId IdType="pmc">PMC7392898</ArticleId><ArticleId IdType="pubmed">32733001</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong T.R. Therapies for coronaviruses. Part I of II -- viral entry inhibitors. Expert Opin Ther Pat. 2009;19(3):357–367. doi: 10.1517/13543770802609384.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/13543770802609384</ArticleId><ArticleId IdType="pubmed">19449500</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Zhang W., Hu Y., Tong X., Zheng S., et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. doi: 10.1001/jama.2020.10044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.10044</ArticleId><ArticleId IdType="pmc">PMC7270883</ArticleId><ArticleId IdType="pubmed">32492084</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao T.T., Qian J.D., Zhu W.Y., Wang Y., Wang G.Q. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6):556–563. doi: 10.1002/jmv.25729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25729</ArticleId><ArticleId IdType="pmc">PMC7217143</ArticleId><ArticleId IdType="pubmed">32104907</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson B.N., Feldmann F., Schwarz B., Meade-White K., Porter D.P., et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2. Nature. 2020;585(7824):273–276. doi: 10.1038/s41586-020-2423-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2423-5</ArticleId><ArticleId IdType="pmc">PMC7486271</ArticleId><ArticleId IdType="pubmed">32516797</ArticleId></ArticleIdList></Reference><Reference><Citation>Udwadia Z.F., Singh P., Barkate H., Patil S., Rangwala S., et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62–71. doi: 10.1016/j.ijid.2020.11.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.11.142</ArticleId><ArticleId IdType="pmc">PMC7668212</ArticleId><ArticleId IdType="pubmed">33212256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan Q., Yan Y., Zhang G., Xia S., Zhou J., et al. Clinical development of antivirals against SARS-CoV-2 and its variants. Curr Res Micro Sci. 2024;6 doi: 10.1016/j.crmicr.2023.100208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmicr.2023.100208</ArticleId><ArticleId IdType="pmc">PMC10750039</ArticleId><ArticleId IdType="pubmed">38149085</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X., Chen H., Song Y., Qin Z., Xu L., et al. Advancements, challenges and future perspectives on peptide-based drugs: focus on antimicrobial peptides. Eur J Pharm Sci. 2023;181 doi: 10.1016/j.ejps.2022.106363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2022.106363</ArticleId><ArticleId IdType="pubmed">36529161</ArticleId></ArticleIdList></Reference><Reference><Citation>Case J.B., Chen R.E., Cao L., Ying B., Winkler E.S., et al. Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host Microbe. 2021;29(7):1151–1161. doi: 10.1016/j.chom.2021.06.008. e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.008</ArticleId><ArticleId IdType="pmc">PMC8221914</ArticleId><ArticleId IdType="pubmed">34192518</ArticleId></ArticleIdList></Reference><Reference><Citation>Aloul K.M., Nielsen J.E., Defensor E.B., Lin J.S., Fortkort J.A., et al. Upregulating human cathelicidin antimicrobial peptide LL-37 expression may prevent severe COVID-19 inflammatory responses and reduce microthrombosis. Front Immunol. 2022;13 doi: 10.3389/fimmu.2022.880961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.880961</ArticleId><ArticleId IdType="pmc">PMC9134243</ArticleId><ArticleId IdType="pubmed">35634307</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Zhao Z., Zhou D., Chen Y., Hong W., et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides. 2011;32(7):1518–1525. doi: 10.1016/j.peptides.2011.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2011.05.015</ArticleId><ArticleId IdType="pmc">PMC7115635</ArticleId><ArticleId IdType="pubmed">21620914</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L., Liu Q., Zhu Y., Chan K.H., Qin L., et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067. doi: 10.1038/ncomms4067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4067</ArticleId><ArticleId IdType="pmc">PMC7091805</ArticleId><ArticleId IdType="pubmed">24473083</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Yan L., Xu W., Agrawal A.S., Algaissi A., et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019;5(4) doi: 10.1126/sciadv.aav4580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aav4580</ArticleId><ArticleId IdType="pmc">PMC6457931</ArticleId><ArticleId IdType="pubmed">30989115</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Chen H., Huang J., He B. CD47Binder: identify CD47 binding peptides by combining next-generation phage display data and multiple peptide descriptors. Inter Sci. 2023;15(4):578–589. doi: 10.1007/s12539-023-00575-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12539-023-00575-x</ArticleId><ArticleId IdType="pubmed">37389722</ArticleId></ArticleIdList></Reference><Reference><Citation>He B., Li B., Chen X., Zhang Q., Lu C., et al. PDL1Binder: identifying programmed cell death ligand 1 binding peptides by incorporating next-generation phage display data and different peptide descriptors. Front Microbiol. 2022;13 doi: 10.3389/fmicb.2022.928774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.928774</ArticleId><ArticleId IdType="pmc">PMC9335124</ArticleId><ArticleId IdType="pubmed">35910615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Huang J., He B. AntiDMPpred: a web service for identifying anti-diabetic peptides. PeerJ. 2022;10 doi: 10.7717/peerj.13581.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.13581</ArticleId><ArticleId IdType="pmc">PMC9205309</ArticleId><ArticleId IdType="pubmed">35722269</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeller M., Kang R.J.D., Bolt H.L., Gomes Dos Santos A.L., Weinmann A.L., et al. Sequence-based prediction of the intrinsic solubility of peptides containing non-natural amino acids. Nat Commun. 2023;14(1):7475. doi: 10.1038/s41467-023-42940-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-42940-w</ArticleId><ArticleId IdType="pmc">PMC10656490</ArticleId><ArticleId IdType="pubmed">37978172</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallorin L., Wang J., Kim W.E., Sahu S., Kosa N.M., et al. Discovering de novo peptide substrates for enzymes using machine learning. Nat Commun. 2018;9(1):5253. doi: 10.1038/s41467-018-07717-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07717-6</ArticleId><ArticleId IdType="pmc">PMC6286390</ArticleId><ArticleId IdType="pubmed">30531862</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj G., O'Connor J., Rettie S., Huang Y.H., Ramelot T.A., et al. Accurate de novo design of membrane-traversing macrocycles. Cell. 2022;185(19):3520–3532. doi: 10.1016/j.cell.2022.07.019. e26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.07.019</ArticleId><ArticleId IdType="pmc">PMC9490236</ArticleId><ArticleId IdType="pubmed">36041435</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Y., Wang Z., Jhong J.H., Lee T.Y. Identifying anti-coronavirus peptides by incorporating different negative datasets and imbalanced learning strategies. Brief Bioinform. 2021;22(2):1085–1095. doi: 10.1093/bib/bbaa423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbaa423</ArticleId><ArticleId IdType="pmc">PMC7929366</ArticleId><ArticleId IdType="pubmed">33497434</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurata H., Tsukiyama S., Manavalan B. iACVP: markedly enhanced identification of anti-coronavirus peptides using a dataset-specific word2vec model. Brief Bioinform. 2022;23(4) doi: 10.1093/bib/bbac265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbac265</ArticleId><ArticleId IdType="pubmed">35772910</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Chen X., Li B., Lu C., Yang S., et al. A database of anti-coronavirus peptides. Sci Data. 2022;9(1):294. doi: 10.1038/s41597-022-01394-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41597-022-01394-3</ArticleId><ArticleId IdType="pmc">PMC9192597</ArticleId><ArticleId IdType="pubmed">35697698</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhong J.H., Yao L., Pang Y., Li Z., Chung C.R., et al. dbAMP 2.0: updated resource for antimicrobial peptides with an enhanced scanning method for genomic and proteomic data. Nucleic Acids Res. 2022;50(D1):D460–D470. doi: 10.1093/nar/gkab1080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab1080</ArticleId><ArticleId IdType="pmc">PMC8690246</ArticleId><ArticleId IdType="pubmed">34850155</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramson J., Adler J., Dunger J., Evans R., Green T., et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024;630 doi: 10.1038/s41586-024-07487-w. (Jun 13 Tn 8016)</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07487-w</ArticleId><ArticleId IdType="pmc">PMC11168924</ArticleId><ArticleId IdType="pubmed">38718835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabsch WS C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 1983;22(12):2577–2637. doi: 10.1002/bip.360221211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bip.360221211</ArticleId><ArticleId IdType="pubmed">6667333</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo-Chen C. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr Proteom. 2009;6(4):262–274. doi: 10.2174/157016409789973707.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157016409789973707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Zhao P., Li F., Leier A., Marquez-Lago T.T., et al. iFeature: a python package and web server for features extraction and selection from protein and peptide sequences. Bioinformatics. 2018;34(14):2499–2502. doi: 10.1093/bioinformatics/bty140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty140</ArticleId><ArticleId IdType="pmc">PMC6658705</ArticleId><ArticleId IdType="pubmed">29528364</ArticleId></ArticleIdList></Reference><Reference><Citation>Guntuboina C., Das A., Mollaei P., Kim S., Farimani A.B. PeptideBERT: A Language Model Based on Transformers for Peptide Property Prediction.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10683064</ArticleId><ArticleId IdType="pubmed">37956397</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco P., Torgo L., Ribeiro R.P. (2017) SMOGN: a Pre-processing Approach for Imbalanced Regression.</Citation></Reference><Reference><Citation>Liang X., Li F., Chen J., Li J., Wu H., et al. Large-scale comparative review and assessment of computational methods for anti-cancer peptide identification. Brief Bioinform. 2021;22(4) doi: 10.1093/bib/bbaa312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbaa312</ArticleId><ArticleId IdType="pmc">PMC8294543</ArticleId><ArticleId IdType="pubmed">33316035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Zhu F., Yu Q., Zhu X. Identifying DNA-binding proteins based on multi-features and LASSO feature selection. Biopolymers. 2021;112(2) doi: 10.1002/bip.23419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bip.23419</ArticleId><ArticleId IdType="pubmed">33476047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr W.T., Anderson A., Xia H., Braun E.S., Lau E.P., et al. Parameter selection in mutual information-based feature selection in automated diagnosis of multiple epilepsies using scalp EEG. Int Workshop Pattern Recognit Neuroimaging. 2012:45–48. doi: 10.1109/PRNI.2012.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/PRNI.2012.27</ArticleId><ArticleId IdType="pmc">PMC4169072</ArticleId><ArticleId IdType="pubmed">25241830</ArticleId></ArticleIdList></Reference><Reference><Citation>Montesinos-Lopez O.A., Crespo-Herrera L., Saint Pierre C., Bentley A.R., de la Rosa-Santamaria R., et al. Do feature selection methods for selecting environmental covariables enhance genomic prediction accuracy? Front Genet. 2023;14 doi: 10.3389/fgene.2023.1209275.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2023.1209275</ArticleId><ArticleId IdType="pmc">PMC10405933</ArticleId><ArticleId IdType="pubmed">37554404</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng H., Long F., Ding C. Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell. 2005;27(8):1226–1238. doi: 10.1109/TPAMI.2005.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/TPAMI.2005.159</ArticleId><ArticleId IdType="pubmed">16119262</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc: Ser B (Methodol) 2018;58(1):267–288. doi: 10.1111/j.2517-6161.1996.tb02080.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2517-6161.1996.tb02080.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvandeh S., Yeh H.W., Paulus M.P., McKinney B.A. Consensus features nested cross-validation. Bioinformatics. 2020;36(10):3093–3098. doi: 10.1093/bioinformatics/btaa046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa046</ArticleId><ArticleId IdType="pmc">PMC7776094</ArticleId><ArticleId IdType="pubmed">31985777</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmons P.B., Hewage C.M. ENNAVIA is a novel method which employs neural networks for antiviral and anti-coronavirus activity prediction for therapeutic peptides. Brief Bioinform. 2021;22(6) doi: 10.1093/bib/bbab258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab258</ArticleId><ArticleId IdType="pmc">PMC8575049</ArticleId><ArticleId IdType="pubmed">34297817</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Liu H., Wu T., Zhu Y., Zhou Y., et al. ACP-dnnel: anti-coronavirus peptides' prediction based on deep neural network ensemble learning. Amino Acids. 2023;55(9):1121–1136. doi: 10.1007/s00726-023-03300-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00726-023-03300-6</ArticleId><ArticleId IdType="pubmed">37402073</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi A., Tandon H., Kumar M. AVP-IC50 pred: multiple machine learning techniques-based prediction of peptide antiviral activity in terms of half maximal inhibitory concentration (IC50) Biopolymers. 2015;104(6):753–763. doi: 10.1002/bip.22703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bip.22703</ArticleId><ArticleId IdType="pmc">PMC7161829</ArticleId><ArticleId IdType="pubmed">26213387</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang G., Liu Z., Chen D. Human coronaviruses: origin, host and receptor. J Clin Virol. 2022;155 doi: 10.1016/j.jcv.2022.105246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105246</ArticleId><ArticleId IdType="pmc">PMC9301904</ArticleId><ArticleId IdType="pubmed">35930858</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaei Khoei T., Ould Slimane H., Kaabouch N. Deep learning: systematic review, models, challenges, and research directions. Neural Comput Appl. 2023;35(31):23103–23124. doi: 10.1007/s00521-023-08957-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00521-023-08957-4</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>